安进(AMGN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AMGN 安进

盘后交易 09-14 17:05:39 EDT

381.50

+4.15

+1.10%

盘后381.97

+0.47+0.12%

17:00 EDT

最高384.61	最低376.76	成交量261.93万
今开381.94	昨收377.35	日振幅2.08%
总市值2,054亿	流通市值2,049亿	总股本5.38亿
成交额9.96亿	换手率0.49%	流通股本5.37亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AMGN","market":"US","secType":"STK","nameCN":"安进","latestPrice":381.5,"timestamp":1789416000000,"preClose":377.35,"halted":0,"volume":2619273,"hourTrading":{"tag":"盘后","latestPrice":381.97,"preClose":381.5,"latestTime":"17:00 EDT","volume":241714,"amount":92213407.572,"timestamp":1789419601230,"change":0.47,"changeRate":0.001232,"amplitude":0.005583},"delay":0,"changeRate":0.010997747449317549,"floatShares":536994627,"shares":538480671,"eps":16.1,"marketStatus":"盘后交易","change":4.15,"latestTime":"09-14 17:05:39 EDT","open":381.94,"high":384.61,"low":376.76,"amount":996195172.1271,"amplitude":0.020803,"askPrice":382.76,"askSize":1,"bidPrice":379.51,"bidSize":20,"shortable":3,"etf":0,"ttmEps":16.1,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1789430400000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":423288000000,"exchange":"NASDAQ","adjPreClose":377.35,"dividendRate":0.025688,"preHourTrading":{"tag":"盘前","latestPrice":382.52,"preClose":377.35,"latestTime":"09:29 EDT","volume":13557,"amount":5140153.90296,"timestamp":1789392599999,"change":5.17,"changeRate":0.013701,"amplitude":0.017464},"postHourTrading":{"tag":"盘后","latestPrice":381.97,"preClose":381.5,"latestTime":"17:00 EDT","volume":241714,"amount":92213407.572,"timestamp":1789419601230,"change":0.47,"changeRate":0.001232,"amplitude":0.005583},"volumeRatio":0.765178,"optionData":{"bulkOrders":[{"symbol":"AMGN","call":false,"expireDate":1792123200000,"strike":"460.0","timestamp":1789414709534,"price":79.6,"volume":2700,"amount":21492000,"type":"-"},{"symbol":"AMGN","call":false,"expireDate":1789704000000,"strike":"440.0","timestamp":1789414709534,"price":59.6,"volume":2500,"amount":14900000,"type":"-"}]},"impliedVol":0.2841,"impliedVolPercentile":0.4781},"requestUrl":"/m/hq/s/AMGN","defaultTab":"news","newsList":[{"id":"2666712586","title":"安进（AMGN）联合疗法III期临床达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2666712586","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666712586?lang=zh_cn&edition=full","pubTime":"2026-09-09 16:59","pubTimestamp":1788944360,"startTime":"0","endTime":"0","summary":"金吾财经 | 安进公布，双特异性T细胞衔接器Imdelltra联合阿斯利康PD-L1抑制剂英飞凡，在广泛期小细胞肺癌的后期临床试验中实现总生存期延长。这家加州生物制药企业披露III期DeLLphi-305研究中期数据，该试验达成广泛期小细胞肺癌患者总生存期主要终点。该项全球试验评估该组合作为一线维持治疗，受试者既往接受过包含英飞凡的治疗且病情未发生进展。研究同时达成无进展生存期、客观缓解率两项次要终点。","market":"nz","thumbnail":"https://static.szfiu.com/news/20210810/NjNkZWQ4NGZiN2I3MDYxNDlhOTlmZGM4ZTUwODkzNDUzNTE2.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NjNkZWQ4NGZiN2I3MDYxNDlhOTlmZGM4ZTUwODkzNDUzNTE2.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305840","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRZ35.SGD","AMGN","BK4566","LU0109394709.USD","LU2468319806.SGD","LU2237443978.SGD","LU2112291526.USD","LU2237443895.HKD","BK4581","BIB","AZNH","PJP","LU0889565916.HKD","IE0002141913.USD","LU0128525929.USD","LU0122379950.USD","IE00BFTCPJ56.SGD","LU2242652126.USD","BBH","IE00B4R5TH58.HKD","LU1571399168.USD","BK4533","LU1023059063.AUD","LU0058720904.USD","LU0868494617.USD","LU2456880835.USD","LU0708994859.HKD","IBBQ","LU2242646821.SGD","LU0289739699.SGD","LU0432979614.USD","LU1829250122.USD","IBB","LU2236285917.USD","IE00B2B36J28.USD","PBE","LU2237443622.USD","LU0029864427.USD","BK4139","BK4568","BK4534","BK4585","LU2237443382.USD","LU1267930573.SGD","LU2462157665.USD","LU2089984988.USD","TBXU","SG9999001440.SGD","AZN","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666730093","title":"诺华(NVS.US)心血管疗法试验“爆雷”拖累安进(AMGN.US)：股价暴跌创十年之最，BMO火速下调评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2666730093","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666730093?lang=zh_cn&edition=full","pubTime":"2026-09-09 14:43","pubTimestamp":1788936181,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，受诺华制药近日宣布其与Ionis Pharmaceuticals联合开发的一款心脏病疗法在后期临床试验中遭遇挫折影响，安进股价周二下跌超10%，创下自2016年以来最大单日跌幅。该药物由安进与Arrowhead Pharmaceuticals及Royalty Pharma合作开发，研究设计与此前试验相似。Skorney在报告中维持对安进的“跑赢大盘”评级，但坦言：“尽管两个项目之间存在关键差异，有可能助力安进最终成功，但我们认为更可能出现类似的不利结果。”他维持对安进450美元的目标价。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493795.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["NVS","AMGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666309213","title":"安进-阿斯利康肺癌联合用药在后期临床试验中显著提升生存率","url":"https://stock-news.laohu8.com/highlight/detail?id=2666309213","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666309213?lang=zh_cn&edition=full","pubTime":"2026-09-09 10:39","pubTimestamp":1788921579,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4139","BK4588","BK4534","IE00B4R5TH58.HKD","LU2468319806.SGD","IE00BJT1NW94.SGD","TBXU","LU2242652126.USD","LU0289739699.SGD","LU0320765992.SGD","PBE","BMED","LU2089984988.USD","BK4533","PJP","LU2112291526.USD","IE00B2B36J28.USD","BK4599","MDTX","LU1571399168.USD","AMGN","LU0868494617.USD","LU1057294990.SGD","IE0002141913.USD","PSYK","IE00BFTCPJ56.SGD","LU0122379950.USD","IE0009355771.USD","IBBQ","LU2242646821.SGD","IE00BJJMRZ35.SGD","LU0058720904.USD","BK4566","IBBJ","LU0889565916.HKD","IBB","LU1023059063.AUD","SG9999001440.SGD","LU1061106388.HKD","BBH","BIB","LU1983299246.USD","BK4585","BK4581","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112638879","title":"市场风向标：安进股价遭受重创","url":"https://stock-news.laohu8.com/highlight/detail?id=1112638879","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112638879?lang=zh_cn&edition=full","pubTime":"2026-09-09 05:35","pubTimestamp":1788903338,"startTime":"0","endTime":"0","summary":"“这对安进而言，堪称最糟糕的结局。”——巴克莱分析师艾米丽·菲尔德如此评价。此前，诺华制药公布了其心脏病药物令人失望的试验结果，这一披露不仅让诺华自身承压，更给安进旗下一款重磅药物蒙上了厚厚的阴影。","market":"hk","thumbnail":"https://static.tigerbbs.com/e5b05f9c7e258c0791b0ff14e4bfadad","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/e5b05f9c7e258c0791b0ff14e4bfadad"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBH","LU0320765992.SGD","LU2242652126.USD","IE0002141913.USD","BK4599","LU0109394709.USD","PJP","BK4534","BK4566","PBE","AMGN","LU1571399168.USD","BK4588","LU1061106388.HKD","LU0122379950.USD","LU1983299246.USD","LU1057294990.SGD","SG9999001440.SGD","IBB","LU2468319806.SGD","LU0058720904.USD","IE00BFTCPJ56.SGD","IE0009355771.USD","BIB","BK4533","BK4585","IE00BJT1NW94.SGD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU0889565916.HKD","LU2112291526.USD","LU1023059063.AUD","TBXU","IBBQ","BK4139","LU0289739699.SGD","BK4581","LU2242646821.SGD","IE00B4R5TH58.HKD","LU2089984988.USD","LU0868494617.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111756325","title":"安进股价或创二十余年来最大单日跌幅","url":"https://stock-news.laohu8.com/highlight/detail?id=1111756325","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111756325?lang=zh_cn&edition=full","pubTime":"2026-09-09 02:23","pubTimestamp":1788891793,"startTime":"0","endTime":"0","summary":"安进公司股价近期重挫逾9%，这一跌幅令这家生物技术巨头有望迎来自2000年10月以来最惨淡的单日表现。此番暴跌的导火索，源于诺华制药宣布其心脏病药物pelacarsen在降低心血管事件风险方面未能优于安慰剂，试验宣告失败。周二，礼来股价小幅下挫1.9%。安进的跌势因BMO资本市场的下调评级而进一步加剧，使其沦为标普500指数和纳斯达克100指数中的最大输家。","market":"hk","thumbnail":"https://static.tigerbbs.com/95977f976807e41662cc4b3ba02269af","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/95977f976807e41662cc4b3ba02269af"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBH","LU0320765992.SGD","LU2242652126.USD","IE0002141913.USD","BK4599","LU0109394709.USD","PJP","BK4534","BK4566","PBE","AMGN","LU1571399168.USD","BK4588","LU1061106388.HKD","LU0122379950.USD","LU1983299246.USD","LU1057294990.SGD","SG9999001440.SGD","04332","IBB","LU2468319806.SGD","LU0058720904.USD","IE00BFTCPJ56.SGD","IE0009355771.USD","BIB","BK4533","BK4585","IE00BJT1NW94.SGD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU0889565916.HKD","LU2112291526.USD","LU1023059063.AUD","TBXU","IBBQ","BK4139","LU0289739699.SGD","BK4581","LU2242646821.SGD","IE00B4R5TH58.HKD","LU2089984988.USD","LU0868494617.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665375527","title":"安进股价下跌7%，创下自2025年6月以来最大单日跌幅。","url":"https://stock-news.laohu8.com/highlight/detail?id=2665375527","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665375527?lang=zh_cn&edition=full","pubTime":"2026-09-08 21:30","pubTimestamp":1788874246,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BIB","LU0058720904.USD","IE0009355771.USD","BK4533","IE00BFTCPJ56.SGD","LU1057294990.SGD","LU2242652126.USD","SG9999001440.SGD","BK4599","LU0109394709.USD","LU0889565916.HKD","IE00BJJMRZ35.SGD","LU2089984988.USD","LU1061106388.HKD","AMGN","BK4139","LU2242646821.SGD","BK4585","LU2112291526.USD","TBXU","IE00B2B36J28.USD","LU0122379950.USD","BK4566","IE00B4R5TH58.HKD","LU1571399168.USD","LU2468319806.SGD","PBE","LU0320765992.SGD","IBBQ","BK4588","LU0289739699.SGD","LU0868494617.USD","PJP","LU1023059063.AUD","BK4581","LU1983299246.USD","IBB","BK4534","IE00BJT1NW94.SGD","IE0002141913.USD","BBH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115495471","title":"安进Phase 3 Dellphi-305研究重大突破：总生存期获益显著优于度伐利尤单抗单药治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1115495471","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115495471?lang=zh_cn&edition=full","pubTime":"2026-09-08 21:07","pubTimestamp":1788872830,"startTime":"0","endTime":"0","summary":"安进公司宣布，其Phase 3 Dellphi-305临床研究取得重大成果——与度伐利尤单抗单独用药相比，该疗法在总生存期上展现出显著且具有临床意义的改善。这一里程碑式的发现，无疑为肿瘤治疗领域注入了新的活力与希望。尽管完整的详细数据尚未全面披露，但安进方面表示，其临床意义及安全性特征将在即将召开的重大学术会议上进行详尽报告。安进公司并未止步于此。随着研发管线的持续推进，安进正逐步兑现其以创新疗法攻克严重疾病的承诺。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0122379950.USD","LU1057294990.SGD","BK4585","BK4581","LU0868494617.USD","BK4599","LU1983299246.USD","LU0058720904.USD","IBB","IE00B4R5TH58.HKD","LU1571399168.USD","SG9999001440.SGD","LU2089984988.USD","PJP","IBBQ","LU0289739699.SGD","BK4588","BBH","BK4534","LU1023059063.AUD","IE0009355771.USD","LU0889565916.HKD","LU2242652126.USD","IE00BJJMRZ35.SGD","BIB","PBE","AMGN","IE00BJT1NW94.SGD","LU0320765992.SGD","LU1061106388.HKD","IE00B2B36J28.USD","LU2242646821.SGD","LU0109394709.USD","IE0002141913.USD","TBXU","LU2112291526.USD","BK4533","IE00BFTCPJ56.SGD","BK4139","BK4566","LU2468319806.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109517247","title":"Imdelltra®联合Imfinzi®在一线广泛期小细胞肺癌中展现里程碑式总生存期改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1109517247","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109517247?lang=zh_cn&edition=full","pubTime":"2026-09-08 21:04","pubTimestamp":1788872687,"startTime":"0","endTime":"0","summary":"Imdelltra®与Imfinzi®的联合疗法，于一线广泛期小细胞肺癌治疗领域，取得了具有划时代意义的总生存期提升。这一突破性进展，不仅为患者带来了新的曙光，也重塑了该领域的治疗格局。从数据层面观察，联合治疗方案的生存获益尤为显著，堪称里程碑式的成就。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B4R5TH58.HKD","LU0868494617.USD","BK4599","IE0002141913.USD","LU2242646821.SGD","IE0009355771.USD","LU0320765992.SGD","LU1983299246.USD","BIB","LU0058720904.USD","IBB","LU1571399168.USD","LU2242652126.USD","IE00BJT1NW94.SGD","LU0289739699.SGD","IE00BJJMRZ35.SGD","BK4534","LU2468319806.SGD","BK4581","IBBQ","SG9999001440.SGD","TBXU","LU2089984988.USD","BK4566","LU1023059063.AUD","LU1057294990.SGD","BBH","IE00B2B36J28.USD","LU0109394709.USD","IE00BFTCPJ56.SGD","LU1061106388.HKD","LU2112291526.USD","LU0889565916.HKD","BK4585","PJP","LU0122379950.USD","BK4588","BK4533","PBE","BK4139","AMGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665387373","title":"BMO下调安进及BioNTech评级至“与大市同步”","url":"https://stock-news.laohu8.com/highlight/detail?id=2665387373","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665387373?lang=zh_cn&edition=full","pubTime":"2026-09-08 20:59","pubTimestamp":1788872377,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IE00BFTCPJ56.SGD","LU0058720904.USD","LU1023059063.AUD","LU2089984988.USD","BK4599","BBH","LU2112291526.USD","LU2242646821.SGD","LU1061106388.HKD","IE0002141913.USD","BK4566","LU2468319806.SGD","LU0889565916.HKD","BK4585","IE00B2B36J28.USD","BK4533","IE00BJJMRZ35.SGD","TBXU","SG9999001440.SGD","LU1983299246.USD","BK4581","IBBQ","LU0320765992.SGD","IE00B4R5TH58.HKD","BK4139","IBB","LU0289739699.SGD","LU0122379950.USD","BK4534","LU2242652126.USD","LU0109394709.USD","PJP","IE00BJT1NW94.SGD","BK4588","IE0009355771.USD","BIB","LU1057294990.SGD","LU1571399168.USD","LU0868494617.USD","PBE","AMGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665326953","title":"美股异动｜安进盘前跌5.4%，诺华同靶点药物III期临床失败，Lp(a)赛道遭重创","url":"https://stock-news.laohu8.com/highlight/detail?id=2665326953","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665326953?lang=zh_cn&edition=full","pubTime":"2026-09-08 17:07","pubTimestamp":1788858422,"startTime":"0","endTime":"0","summary":"消息面上，诺华于9月4日公布，其与Ionis联合开发的降脂药物Pelacarsen，在名为LpHORIZON的III期临床试验中未能达到主要终点。诺华的Pelacarsen是全球首个针对Lp靶点进行心血管结局验证的III期药物。因此，市场担忧情绪蔓延到了同样在开发Lp药物的安进身上。多家分析机构认为，诺华的失败削弱了但并未完全推翻Lp这一靶点的可行性。安进后续公布的Olpasiran完整试验数据，将成为判断该靶点未来走向的关键。","market":"hk","thumbnail":" http://caiji.3g.cnfol.com/colect/202609/08/20260908512020.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202609/08/20260908512020.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260908/32363493.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["LU1983299246.USD","BK4007","BK4566","LU0122379950.USD","LU0320765992.SGD","BK4581","BK4533","LU2468319806.SGD","PPH","LU0211331839.USD","IE00BJT1NW94.SGD","BK4578","LU0320765489.SGD","BK4585","IBBQ","BK4534","IE00BFTCPJ56.SGD","LU2242652126.USD","LU0070302665.USD","AMGN","IBB","LU0868494617.USD","BK4588","LU1057294990.SGD","LU0889565916.HKD","IE00B2B36J28.USD","LU0109394709.USD","BK4532","BBH","LU0289739699.SGD","IE0009355771.USD","LU1061106388.HKD","LU0058720904.USD","PBE","BK4599","BIB","NVS","LU2089984988.USD","MEDX","IE0002141913.USD","IE00BJJMRZ35.SGD","LU1571399168.USD","IE00B4R5TH58.HKD","SG9999001440.SGD","PJP","LU2112291526.USD","LU1023059063.AUD","BK4139","TBXU","LU0208291251.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665258833","title":"安进股价盘前下跌5.4%；竞争对手诺华的胆固醇药物后期临床试验失败。","url":"https://stock-news.laohu8.com/highlight/detail?id=2665258833","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665258833?lang=zh_cn&edition=full","pubTime":"2026-09-08 16:28","pubTimestamp":1788856084,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MEDX","IE00BJJMRZ35.SGD","AMGN","BK4566","LU0109394709.USD","LU1057294990.SGD","PPH","PSYK","LU2468319806.SGD","LU2112291526.USD","BK4581","IE00BJT1NW94.SGD","BIB","PJP","LU0889565916.HKD","IE0002141913.USD","LU0122379950.USD","IE00BFTCPJ56.SGD","LU2242652126.USD","LU0320765992.SGD","BBH","LU0208291251.USD","BK4588","BK4533","BMED","LU1023059063.AUD","LU0058720904.USD","LU0868494617.USD","BK4532","IBBQ","LU2242646821.SGD","LU0289739699.SGD","IBB","LU1983299246.USD","BK4007","IBBJ","NVS","PBE","BK4578","LU1061106388.HKD","LU0320765489.SGD","MDTX","LU0070302665.USD","LU0211331839.USD","BK4534","BK4585","TBXU","SG9999001440.SGD","LU2089984988.USD","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100170776","title":"异动解读｜安进盘前下跌5.08%，诺华Lp(a)心脏药III期折戟波及同赛道公司","url":"https://stock-news.laohu8.com/highlight/detail?id=1100170776","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100170776?lang=zh_cn&edition=full","pubTime":"2026-09-08 16:03","pubTimestamp":1788854584,"startTime":"0","endTime":"0","summary":"9月8日，安进盘前下跌5.08%，报414.54美元/股，成交额12.85万美元。该试验入组8323名患者，历时6年追踪，是全球首个验证\"降低Lp能否减少心血管事件\"的结局试验，其失败令市场对整个Lp靶点赛道的商业前景产生担忧。安进正在开发类似机制的Lp靶向药物Olpasiran，市场担忧该药未来临床前景同样面临不确定性，股价因此承压。分析机构指出，pelacarsen的失败尚不足以直接否定Lp降低带来心血管获益的逻辑，但对该治疗路径确已产生负面影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"诺华心脏药试验折戟，安进同赛道承压","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665349003","title":"富国银行上调安进目标价至435美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2665349003","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665349003?lang=zh_cn&edition=full","pubTime":"2026-09-08 11:12","pubTimestamp":1788837128,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["UDN","BK4566","AMGN","UUP","IE00B2B36J28.USD","LU1571399168.USD","LU1061106388.HKD","LU2468319806.SGD","LU0889565916.HKD","BK4139","BK4533","LU1057294990.SGD","BK4582","BIB","IE00B4R5TH58.HKD","LU0109394709.USD","LU1983299246.USD","LU2112291526.USD","BBH","IE00BFTCPJ56.SGD","IBB","PGF","IE0009355771.USD","PBE","LU1023059063.AUD","LU0058720904.USD","PJP","LU2242646821.SGD","BK4585","LU0868494617.USD","BK4534","LU2242652126.USD","BK4581","LU0289739699.SGD","LU2089984988.USD","SG9999001440.SGD","LU0320765992.SGD","IE0002141913.USD","BK4599","IE00BJJMRZ35.SGD","LU0122379950.USD","TBXU","IBBQ","IE00BJT1NW94.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154139665","title":"异动解读｜安进夜盘下跌5.27%，报414.18美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1154139665","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154139665?lang=zh_cn&edition=full","pubTime":"2026-09-08 08:00","pubTimestamp":1788825631,"startTime":"0","endTime":"0","summary":"9月8日，安进夜盘下跌5.27%，报414.18美元/股，成交额1.2万美元。安进所在的生物科技行业中，个股中，Moderna涨0.12%，艾伯维公司跌0.42%，吉利德科学跌0.32%，再生元制药公司跌0.41%，福泰制药跌0.69%。安进公司于1980年在加利福尼亚成立，专注于发现、开发、制造和交付创新药物，是全球领先的独立生物技术公司之一，聚焦高度未满足的医疗需求领域。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665392789","title":"一周两度受挫！诺华(NVS.US)心脏病重磅药III期折戟，股价大跌安进(AMGN.US)“躺枪”","url":"https://stock-news.laohu8.com/highlight/detail?id=2665392789","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665392789?lang=zh_cn&edition=full","pubTime":"2026-09-07 15:15","pubTimestamp":1788765302,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞士制药巨头诺华制药再遭临床试验打击——一周之内，该公司第二项重磅候选药物在后期研究中折戟。此次失利的是其潜在明星心脏病药物pelacarsen。受此消息影响，诺华在美上市股票上周五常规交易结束后一度下跌逾7%。开发类似心脏药物的安进股价上周五盘后也下挫近6%。诺华正寄望于一系列新药来支撑增长，以应对旗下多款重磅产品专利即将到期的压力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492719.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BIB","LU0058720904.USD","IE0009355771.USD","BK4533","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","BK4007","LU1057294990.SGD","MEDX","LU2242652126.USD","SG9999001440.SGD","BK4599","LU0070302665.USD","LU0109394709.USD","IE00BJJMRZ35.SGD","LU0208291251.USD","LU0889565916.HKD","LU0211331839.USD","LU2089984988.USD","LU1061106388.HKD","AMGN","BK4532","BK4139","LU2242646821.SGD","BK4585","LU2112291526.USD","LU0320765489.SGD","TBXU","IE00B2B36J28.USD","LU0122379950.USD","BK4566","IE00B4R5TH58.HKD","LU1571399168.USD","LU2468319806.SGD","PBE","LU0320765992.SGD","IBBQ","BK4588","LU0289739699.SGD","LU0868494617.USD","NVS","PPH","PJP","LU1023059063.AUD","BK4581","IBB","BK4534","BK4578","IE0002141913.USD","BBH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172857741","title":"异动解读｜安进盘后下跌5.08%，报411.4美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1172857741","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172857741?lang=zh_cn&edition=full","pubTime":"2026-09-05 04:32","pubTimestamp":1788553975,"startTime":"0","endTime":"0","summary":"9月5日，安进盘后下跌5.08%，报411.4美元/股，成交额4705.34万美元。安进所在的生物科技行业中，个股中，Moderna跌0.41%，艾伯维公司跌0.06%，吉利德科学跌0.14%，再生元制药公司涨0.12%，福泰制药跌0.39%。安进公司于1980年在加利福尼亚成立，专注于发现、开发、制造和交付创新药物，是全球领先的独立生物技术公司之一，聚焦高度未满足的医疗需求领域。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664194548","title":"安进（AMGN）罕见病药物Tavneos将于27年3月1日被彻底撤销英国上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2664194548","media":"金吾财讯","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664194548?lang=zh_cn&edition=full","pubTime":"2026-09-02 19:59","pubTimestamp":1788350357,"startTime":"0","endTime":"0","summary":"金吾财讯 | 英国药品监管机构MHRA宣布，暂停安进（AMGN）罕见病药物Avacopan Vifor（原商品名Tavneos）用于新患者，监管认定支撑该药物获批的关键临床试验数据已不可靠。该药2022年在英国获批，用于治疗两种罕见血管炎症自身免疫病。安进持有美国地区权益，由CSL集团（CSLLY）旗下CSLVifor负责英国等海外市场销售。新规9月1日落地，不再允许新患者启用该药物；为保障现有患者安全，设置6个月过渡用药期，2027年3月1日将彻底撤销其英国上市许可，现有患者可在此期间逐步更换替代治疗方案。安进方面公开表示不认可监管机构的决定，担忧该举措会对罕见病患者造成负面影响。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210625/OTU2NGE4NGJmZTIzZDc2N2YxYmJkM2MyMjUzODQzOTQ1NzY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/OTU2NGE4NGJmZTIzZDc2N2YxYmJkM2MyMjUzODQzOTQ1NzY=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305627","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","LU0109394709.USD","AZNH","AMGN","IE00B4R5TH58.HKD","LU0122379950.USD","LU1571399168.USD","PBE","LU2112291526.USD","BK4533","LU0058720904.USD","LU2468319806.SGD","LU2089984988.USD","PJP","BK4588","IBB","LU0320765992.SGD","LU1057294990.SGD","LU2242652126.USD","LU0289739699.SGD","LU0868494617.USD","LU1061106388.HKD","BK4581","SG9999001440.SGD","TBXU","IE00BFTCPJ56.SGD","IPOS","BK4566","LU1983299246.USD","IE0002141913.USD","IE00BJJMRZ35.SGD","BK4139","LU2242646821.SGD","BBH","BIB","IBBQ","IE00B2B36J28.USD","IE0009355771.USD","IE00BJT1NW94.SGD","BK4599","BK4534","BK4585","LU1023059063.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148791645","title":"英国药品与健康产品管理局：通知上市许可持有方，自9月1日起暂停新患者使用、供应及销售Avacopan Vifor","url":"https://stock-news.laohu8.com/highlight/detail?id=1148791645","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148791645?lang=zh_cn&edition=full","pubTime":"2026-09-01 17:35","pubTimestamp":1788255329,"startTime":"0","endTime":"0","summary":"英国药品与健康产品管理局（MHRA）已正式告知上市许可持有方，关于暂停Avacopan Vifor用于新患者的使用、供应及销售的相关决定。该措施自9月1日起生效。此番调整涉及该药物的市场流通环节，意在规范其临床应用范围。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","BK4581","PJP","BK4599","LU1571399168.USD","TBXU","IE0002141913.USD","BBH","LU0889565916.HKD","LU2468319806.SGD","IBB","BK4585","PBE","LU0868494617.USD","SG9999001440.SGD","LU1983299246.USD","LU1061106388.HKD","IE0009355771.USD","IE00BJJMRZ35.SGD","LU2242646821.SGD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","BK4534","LU2242652126.USD","LU2112291526.USD","IE00BFTCPJ56.SGD","LU0109394709.USD","BK4139","LU1023059063.AUD","IE00BJT1NW94.SGD","IBBQ","LU2089984988.USD","BK4588","AMGN","LU0320765992.SGD","BIB","BK4566","LU0122379950.USD","BK4533","LU0058720904.USD","LU1057294990.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663778550","title":"安进（AMGN）降脂药Repatha新临床数据：可降低未发生心梗或中风高危患者20%死亡风险","url":"https://stock-news.laohu8.com/highlight/detail?id=2663778550","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663778550?lang=zh_cn&edition=full","pubTime":"2026-08-31 18:48","pubTimestamp":1788173287,"startTime":"0","endTime":"0","summary":"研究结果显示，对于既往未发生过心肌梗死或中风的高危成年患者，在接受他汀类或其他降脂疗法的基础上加用Repatha，可显著降低20%的全因死亡风险，同时有效降低心血管死亡率。数据显示，Repatha能在治疗开启最早6个月内降低心梗风险，且将患者低密度脂蛋白胆固醇中位数降低至45mg/dL，远优于安慰剂组的109mg/dL。此外，欧盟委员会已于2026年8月批准扩大Repatha在欧洲的适应症，用于确诊或高危确诊的动脉粥样硬化性心血管疾病成年患者降低心血管风险。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250107/Mjk1NzA2YjQxMDg1MTQ0MjI1MzE=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/Mjk1NzA2YjQxMDg1MTQ0MjI1MzE=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305491","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","LU1983299246.USD","AMGN","BK4581","LU2468319806.SGD","LU2242646821.SGD","LU0289739699.SGD","IE00BFTCPJ56.SGD","LU0889565916.HKD","IE0002141913.USD","LU1057294990.SGD","LU2089984988.USD","LU2112291526.USD","BIB","BK4588","LU2242652126.USD","LU1061106388.HKD","BK4566","IE00BJJMRZ35.SGD","LU0320765992.SGD","LU0058720904.USD","LU1571399168.USD","IBB","PBE","PJP","IBBQ","BBH","TBXU","IE00BJT1NW94.SGD","BK4139","LU0868494617.USD","LU1023059063.AUD","SG9999001440.SGD","BK4534","BK4599","LU0109394709.USD","LU0122379950.USD","BK4533","IE0009355771.USD","BK4585","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146489142","title":"Tezspire®在嗜酸性食管炎III期临床试验中展现积极成果，共同主要终点及所有关键次要终点全面达标","url":"https://stock-news.laohu8.com/highlight/detail?id=1146489142","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146489142?lang=zh_cn&edition=full","pubTime":"2026-08-27 14:00","pubTimestamp":1787810443,"startTime":"0","endTime":"0","summary":"Tezspire在针对嗜酸性食管炎的III期临床试验中取得了令人瞩目的积极结果。该试验不仅成功达到了共同主要终点，而且所有关键次要终点也悉数告捷。Tezspire的优异表现，标志着该领域治疗可能迎来重大变革。共同主要终点的同时达成，以及关键次要终点的全面覆盖，充分验证了Tezspire的疗效一致性和临床获益的广泛性。业内专家指出，Tezspire的这项研究成果，不仅巩固了其在炎症性疾病治疗领域的地位，更可能为后续的监管审批和市场推广奠定坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1983299246.USD","LU0320765992.SGD","LU2242646821.SGD","IE0002141913.USD","LU1061106388.HKD","LU1057294990.SGD","BK4139","PJP","LU0868494617.USD","BBH","LU0889565916.HKD","SG9999001440.SGD","LU2089984988.USD","BK4585","IBB","LU0109394709.USD","LU2468319806.SGD","IE00BFTCPJ56.SGD","IE0009355771.USD","IE00BJT1NW94.SGD","LU1571399168.USD","LU1023059063.AUD","LU2112291526.USD","IE00B4R5TH58.HKD","IE00B2B36J28.USD","BIB","BK4581","IE00BJJMRZ35.SGD","BK4534","BK4566","LU0289739699.SGD","IBBQ","BK4533","BK4599","LU0058720904.USD","LU0122379950.USD","AMGN","LU2242652126.USD","TBXU","PBE","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.amgen.com","stockEarnings":[{"period":"1week","weight":-0.137},{"period":"1month","weight":-0.0933},{"period":"3month","weight":0.0624},{"period":"6month","weight":0.0304},{"period":"1year","weight":0.3347},{"period":"ytd","weight":0.1529}],"compareEarnings":[{"period":"1week","weight":-0.0077},{"period":"1month","weight":-0.0106},{"period":"3month","weight":0.0304},{"period":"6month","weight":0.154},{"period":"1year","weight":0.1622},{"period":"ytd","weight":0.1208}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"安进公司于1980年在加利福尼亚成立，并于1987年成为特拉华州的一家公司。该公司发现、开发、制造和交付创新药物，以对抗世界上一些最棘手的疾病。该公司专注于高度未满足的医疗需求领域，并利用其专业知识努力寻求能够显著改善人们生活的解决方案，同时还能减轻疾病带来的社会和经济负担。该公司在40多年前帮助启动了生物技术产业，并已成长为世界领先的独立生物技术公司之一。","yearOnYearQuotes":[{"month":1,"riseRate":0.651163,"avgChangeRate":0.034336},{"month":2,"riseRate":0.488372,"avgChangeRate":0.00202},{"month":3,"riseRate":0.511628,"avgChangeRate":0.016602},{"month":4,"riseRate":0.44186,"avgChangeRate":-0.003156},{"month":5,"riseRate":0.511628,"avgChangeRate":0.022981},{"month":6,"riseRate":0.511628,"avgChangeRate":0.005534},{"month":7,"riseRate":0.772727,"avgChangeRate":0.052813},{"month":8,"riseRate":0.613636,"avgChangeRate":0.006989},{"month":9,"riseRate":0.5,"avgChangeRate":-0.000533},{"month":10,"riseRate":0.534884,"avgChangeRate":0.021538},{"month":11,"riseRate":0.627907,"avgChangeRate":0.022348},{"month":12,"riseRate":0.627907,"avgChangeRate":0.045446}],"exchange":"NASDAQ","name":"安进","nameEN":"Amgen"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"安进(AMGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供安进(AMGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"安进,AMGN,安进股票,安进股票老虎,安进股票老虎国际,安进行情,安进股票行情,安进股价,安进股市,安进股票价格,安进股票交易,安进股票购买,安进股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"安进(AMGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供安进(AMGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}